Skip to main content
Skip to footer

Akari Therapeutics

AN INNOVATIVE TARGETED ONCOLOGY COMPANY BUILT ON NEXT GENERATION ANTIBODY-DRUG CONJUGATES (ADC) AND A NOVEL DISCOVERY ENGINE

HOME
ABOUT
AREAS OF FOCUS
- Close
- PIPELINE
- POSTERS & PUBLICATIONS
INVESTOR RELATIONS
PRESS
- Close
- PRESS RELEASES
CONTACT US

Main Content

Slide

ADVANCING ANTIBODY DRUG

CONJUGATES WITH NOVEL

IMMUNO-ONCOLOGY PAYLOADS

CORPORATE PRESENTATION CORPORATE PRESENTATION

RECENT PRESS RELEASES

Akari Therapeutics Appoints Leading Cancer Biology and RNA Expert, Prafulla Gokhale, Ph.D., to Scientific Advisory Board

February 26, 2026

Akari Therapeutics Appoints Globally Recognized Expert in RNA Biology and Cancer Research, Olga Anczukow, Ph.D., to its Scientific Advisory Board

February 23, 2026

Akari Therapeutics to Present at the 2026 Biocom Global Partnering & Investor Conference

February 18, 2026

Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing the Company’s Expanded ADC Pipeline

February 11, 2026

Akari Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

February 5, 2026

Footer

FOLLOW US

Privacy Statement

Copyright © 2026 · Akari Therapeutics · Site Designed by Polus Digital, Inc.